Evidence regarding the effect of combination treatment with GLP-1 receptor agonists and SGLT-2 inhibitors in people with type 2 diabetes and CKD comes from a cross-trial simulation analysis of cardiovascular and renal outcome trials. The gene discussed is GLP1R; the disease is chronic kidney disease.